Monoclonal antibodies and emerging medical therapy for CRSwNP and type 2 inflammation.
17 tracked publications · last updated 2026-06-08
Related: AI & Machine Learning · Robotics, Automation & Ergonomics · Navigation, AR-VR, Simulation & 3D Printing · Devices, Implants & Procedures · Endotypes, Biomarkers & Diagnostics · Skull Base Surgery & Reconstruction · Outcomes, Guidelines & Epidemiology
Publications
-
Assessment of MUcociLiary Transport timE in CRSwNP Patients in Treatment With Dupilumab: AMULET Study
Giorli A et al. — Int Forum Allergy Rhinol (2026-06) · Original
Clinical study (AMULET) assessing mucociliary transport time in CRSwNP patients treated with dupilumab.
PubMed · DOI · PMID 42244491 -
Depemokimab: A twice yearly anti-IL 5 biologic for chronic rhinosinusitis with nasal polyps (CRSwNP) - A narrative review
Park MJ et al. — Hum Vaccin Immunother (2026-06) · Review
Narrative review of depemokimab, a long-half-life twice-yearly anti-IL-5 biologic, summarizing ANCHOR-1/-2 Phase 3 results in severe CRSwNP.
PubMed · DOI · PMID 42234701 -
Real-world impact of mepolizumab on symptom control and health utility in severe chronic rhinosinusitis with nasal polyps: the RINOSUR 2.0 multicenter cohort study
Corrales-Millan R et al. — Eur Arch Otorhinolaryngol (2026-06) · Original
12-month real-world multicenter cohort showing mepolizumab improves SNOT-22, polyp score, asthma control, and health utility in severe CRSwNP.
PubMed · DOI · PMID 42228110 -
Mepolizumab improves outcomes in patients with CRSwNP with one or more prior nasal polyp surgeries
Han JK et al. — Rhinology (2026-05) · Original
Post hoc SYNAPSE analysis showing mepolizumab improves polyp, symptom, and SNOT-22 outcomes regardless of prior surgery number, with greatest benefit after a single surgery.
PubMed · DOI · PMID 42206465 -
Rebuilding the Mucociliary Apparatus in ECRS: TSLP/IL-33 Signaling Synergy and the Residual Molecular Scar Following IL-4/13 Blockade
Fujita R et al. — Cells (2026-05) · Original
Transcriptomic study showing dupilumab (IL-4/13 blockade) restores ciliary regulatory programs in eosinophilic CRS but leaves a residual mucus-degradation defect.
PubMed · DOI · PMID 42193919 -
One year mepolizumab outcomes in severe, uncontrolled CRSwNP: a real-life study
De Corso E et al. — Rhinology (2025-12) · Real-world cohort
Real-life 1-year mepolizumab outcomes (n=50): polyp size and symptom improvement.
PubMed · DOI · PMID 40631514 -
[Nasal Polyposis]
Shahal D et al. — Harefuah (2025-12) · Review
Hebrew-language clinical review of nasal polyposis.
PubMed · PMID 41445214 -
Biologics for CRSwNP: Current Landscape and Future Directions
Chiu J et al. — Laryngoscope Investig Otolaryngol (2025-10) · Review
Review of the current biologics landscape and pipeline for CRSwNP.
PubMed · DOI · PMID 41112679 -
Dupilumab versus omalizumab in CRSwNP (EVEREST)
De Corso E et al. — Lancet Respir Med (2025-09) · RCT (Phase 4)
EVEREST — first head-to-head RCT of dupilumab vs omalizumab in CRSwNP.
PubMed · DOI · PMID 41033334 -
An anti-TSLP monoclonal antibody (CM326) for uncontrolled CRSwNP
Xian M et al. — Nat Commun (2025-09) · RCT (Phase 1b/2a)
Phase 1b/2a RCT of anti-TSLP mAb CM326 in uncontrolled CRSwNP, stratified by baseline tissue eosinophils.
PubMed · DOI · PMID 41022848 -
Stapokibart for Severe Uncontrolled CRSwNP (CROWNS-2)
Shen S et al. — JAMA (2025-08) · RCT (Phase 3)
Phase 3 RCT of stapokibart (anti-IL-4Rα) added to intranasal corticosteroids in severe uncontrolled CRSwNP (51 sites).
PubMed · DOI · PMID 40824573 -
Mepolizumab Effectiveness in Severe Asthma With/Without CRSwNP
Schleich F et al. — Allergy (2025-07) · Real-world pooled
Pooled real-world analysis of mepolizumab in severe asthma with and without CRSwNP.
PubMed · DOI · PMID 40590259 -
Effectiveness of Dupilumab in Patients With Type 2 Inflammation: A Real-Life Experience
Torretta S et al. — Ther Adv Allergy Rhinol (2025-06) · Real-world cohort
Integrated real-life experience of dupilumab across type 2 inflammatory disease.
PubMed · DOI · PMID 40487737 -
Epithelial-Derived Alarmins in CRSwNP
Cheng F et al. — Clin Rev Allergy Immunol (2025-06) · Review
Review of epithelial alarmins (TSLP, IL-33, IL-25) as CRSwNP therapeutic targets.
PubMed · DOI · PMID 40533675 -
Reappraisal of Biologic Efficacy from Phase 3 Trials in Refractory CRS
Lipworth BJ et al. — J Allergy Clin Immunol Pract (2025-05) · Review
Critical reappraisal of biologic efficacy across phase 3 CRS trials.
PubMed · DOI · PMID 40340024 -
Eosinophilic granulomatosis with polyangiitis: current status and future perspectives
Kamide Y et al. — Respir Investig (2025-05) · Review
EGPA review — relevant comorbidity/differential in severe eosinophilic CRS.
PubMed · DOI · PMID 40383090 -
Tezepelumab inhibits highly functional truncated TSLP in chronic rhinosinusitis
Oka A et al. — J Allergy Clin Immunol (2025-03) · Mechanistic
Mechanistic evidence that tezepelumab inhibits a truncated, highly functional TSLP isoform in CRS.
PubMed · DOI · PMID 40057283
Sources indexed via PubMed (NCBI). Each entry links to its PubMed record and DOI.